Verified Nov 2026
Other
·
Stockholm, Stockholm County
·
Since 2004
Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. With 200–500 employees and estimated revenues of $100–250 million, the company develops therapies for rare renal and hepatic diseases. Its approved product TARPEYO® treats primary IgA nephropathy, while its pipeline includes setanaxib for primary biliary cholangitis and Alport syndrome.
Calliditas Therapeutics at a glance
Revenue
$100-250M
Est. band
Employees
200-500
Founded
2004
Headquarters
Stockholm, Stockholm County
Industries
Automotive
Electric Vehicles
Medical
Overview
Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. With 200–500 employees and estimated revenues of $100–250 million, the company develops therapies for rare renal and hepatic diseases. Its approved product TARPEYO® treats primary IgA nephropathy, while its pipeline includes setanaxib for primary biliary cholangitis and Alport syndrome.
At a glance
Attribute | Detail |
|---|---|
Founded | 2004 |
Headquarters | Stockholm, Stockholm County |
Employees | 200-500 |
Revenue | $100-250M (estimated) |
What Calliditas Therapeutics makes
The company manufactures and commercializes pharmaceutical products, with a focus on drug discovery, clinical development, and supply chain management for rare disease indications.
Latest developments
2026-09-29 — We are excited to be joining Veloxis Pharmaceuticals and Aicuris Anti-infective Cures as part of Asahi Kasei Therapeutics! Follow us there to stay up to date on our progress to positively impact … | Calliditas Therapeutics (linkedin.com)
2026-03-30 — Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology (prnewswire.com)
2026-03-30 — Calliditas Therapeutics News and Press Releases | PR Newswire (prnewswire.com)
2026-03-30 — Calliditas therapeutics ab | Radio Compass News | PharmaCompass.com (pharmacompass.com)
2025-11-03 — Proud and pleased to announce that Rolf Westerberg joined Team Calliditas Therapeutics as Senior Director, Program and Alliance Management. | Emelie Bäckvall (linkedin.com)
2025-09-25 — 🚨 We’re Hiring! Join Calliditas Therapeutics as a Regional Business Director – Mid-Atlantic Region 🚨 | Evie Callahan (linkedin.com)
Company details
Calliditas operates as a commercial-stage biopharmaceutical firm addressing unmet medical needs in nephrology and hepatology. Calliditas Therapeutics was founded in 2004, has an estimated 200-500 employees, and is headquartered in Stockholm, Stockholm County.
Frequently asked questions
What does Calliditas Therapeutics do?
Calliditas Therapeutics is a specialty biopharmaceutical company headquartered in Stockholm, Sweden, founded in 2004. With 200–500 employees and estimated revenues of $100–250 million, the company develops therapies for rare renal and hepatic diseases. Its approved product TARPEYO® treats primary IgA nephropathy, while its pipeline includes setanaxib for primary biliary cholangitis and Alport syndrome.
Where is Calliditas Therapeutics headquartered?
Calliditas Therapeutics is headquartered in Stockholm, Stockholm County (1 Kungsbron, Stockholm, Stockholm County, 111 22).
When was Calliditas Therapeutics founded?
Calliditas Therapeutics was founded in 2004.
How big is Calliditas Therapeutics?
Calliditas Therapeutics has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
